Literature DB >> 19259792

Cell type-specific targeting with surface-engineered lentiviral vectors co-displaying OKT3 antibody and fusogenic molecule.

Haiguang Yang1, Kye-Il Joo, Leslie Ziegler, Pin Wang.   

Abstract

PURPOSE: The purpose of this study was to investigate the potential of a T-cell-related targeting method using a lentiviral vector-based gene delivery system.
MATERIALS AND METHODS: A lentiviral vector system was constructed by co-incorporating an anti-CD3 antibody (OKT3) and a fusogen into individual viral particles. The incorporation of OKT3 and fusogen was analyzed using confocal microscopy and the in vitro transduction efficiency was evaluated using flow cytometry. Blocking reagents (ammonium chloride (NH(4)Cl) and soluble OKT3 antibody) were added into vector supernatants during transduction to study the mechanism of this two-molecule targeting strategy. To demonstrate the ability of targeted transduction in vivo, Jurkat.CD3 cells were xenografted subcutaneously into the right flank of each mouse and the lentiviral vector was injected subcutaneously on both sides of each mouse 8 h post-injection. Subsequently, the reporter gene (firefly luciferase) expression was monitored using a noninvasive bioluminescence imaging system.
RESULTS: By co-displaying OKT3 and fusogen on the single lentiviral surface, we could achieve targeted delivery of genes to CD3-positive T-cells both in vitro and in vivo.
CONCLUSIONS: These results suggest the potential utility of this engineered lentiviral system as a new tool for cell type-directed gene delivery.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19259792      PMCID: PMC2798122          DOI: 10.1007/s11095-009-9853-y

Source DB:  PubMed          Journal:  Pharm Res        ISSN: 0724-8741            Impact factor:   4.200


  46 in total

1.  Antibody-directed targeting of retroviral vectors via cell surface antigens.

Authors:  K Morizono; G Bristol; Y M Xie ; S K Kung; I S Chen
Journal:  J Virol       Date:  2001-09       Impact factor: 5.103

2.  Cancer regression in patients after transfer of genetically engineered lymphocytes.

Authors:  Richard A Morgan; Mark E Dudley; John R Wunderlich; Marybeth S Hughes; James C Yang; Richard M Sherry; Richard E Royal; Suzanne L Topalian; Udai S Kammula; Nicholas P Restifo; Zhili Zheng; Azam Nahvi; Christiaan R de Vries; Linda J Rogers-Freezer; Sharon A Mavroukakis; Steven A Rosenberg
Journal:  Science       Date:  2006-08-31       Impact factor: 47.728

Review 3.  Altering the tropism of lentiviral vectors through pseudotyping.

Authors:  James Cronin; Xian-Yang Zhang; Jakob Reiser
Journal:  Curr Gene Ther       Date:  2005-08       Impact factor: 4.391

4.  Targeted infection of human cells via major histocompatibility complex class I molecules by Moloney murine leukemia virus-derived viruses displaying single-chain antibody fragment-envelope fusion proteins.

Authors:  M Marin; D Noël; S Valsesia-Wittman; F Brockly; M Etienne-Julan; S Russell; F L Cosset; M Piechaczyk
Journal:  J Virol       Date:  1996-05       Impact factor: 5.103

5.  Retroviral display of antibody fragments; interdomain spacing strongly influences vector infectivity.

Authors:  S Ager; B H Nilson; F J Morling; K W Peng; F L Cosset; S J Russell
Journal:  Hum Gene Ther       Date:  1996-11-10       Impact factor: 5.695

6.  The cholesterol requirement for sindbis virus entry and exit and characterization of a spike protein region involved in cholesterol dependence.

Authors:  Y E Lu; T Cassese; M Kielian
Journal:  J Virol       Date:  1999-05       Impact factor: 5.103

7.  Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors.

Authors:  Oliver J Müller; Felix Kaul; Matthew D Weitzman; Renata Pasqualini; Wadih Arap; Jürgen A Kleinschmidt; Martin Trepel
Journal:  Nat Biotechnol       Date:  2003-08-03       Impact factor: 54.908

8.  Differential cholesterol binding by class II fusion proteins determines membrane fusion properties.

Authors:  M Umashankar; Claudia Sánchez-San Martín; Maofu Liao; Brigid Reilly; Alice Guo; Gwen Taylor; Margaret Kielian
Journal:  J Virol       Date:  2008-07-16       Impact factor: 5.103

9.  Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector.

Authors:  Andrea L Szymczak; Creg J Workman; Yao Wang; Kate M Vignali; Smaroula Dilioglou; Elio F Vanin; Dario A A Vignali
Journal:  Nat Biotechnol       Date:  2004-04-04       Impact factor: 54.908

10.  Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement.

Authors:  Alessandro Aiuti; Sergio Vai; Alessandra Mortellaro; Giulia Casorati; Francesca Ficara; Grazia Andolfi; Giuliana Ferrari; Antonella Tabucchi; Filippo Carlucci; Hans D Ochs; Luigi D Notarangelo; Maria Grazia Roncarolo; Claudio Bordignon
Journal:  Nat Med       Date:  2002-05       Impact factor: 53.440

View more
  12 in total

Review 1.  Immunization delivered by lentiviral vectors for cancer and infectious diseases.

Authors:  Biliang Hu; April Tai; Pin Wang
Journal:  Immunol Rev       Date:  2011-01       Impact factor: 12.988

Review 2.  Role of circular RNAs in brain development and CNS diseases.

Authors:  Suresh L Mehta; Robert J Dempsey; Raghu Vemuganti
Journal:  Prog Neurobiol       Date:  2020-01-10       Impact factor: 11.685

3.  Pseudotyping lentiviral vectors with aura virus envelope glycoproteins for DC-SIGN-mediated transduction of dendritic cells.

Authors:  Steven Froelich; April Tai; Katie Kennedy; Adnan Zubair; Pin Wang
Journal:  Hum Gene Ther       Date:  2011-06-13       Impact factor: 5.695

Review 4.  Precision medicine: In vivo CAR therapy as a showcase for receptor-targeted vector platforms.

Authors:  Alexander Michels; Naphang Ho; Christian J Buchholz
Journal:  Mol Ther       Date:  2022-05-20       Impact factor: 12.910

Review 5.  Lentiviral vectors for immune cells targeting.

Authors:  Steven Froelich; April Tai; Pin Wang
Journal:  Immunopharmacol Immunotoxicol       Date:  2010-06       Impact factor: 2.730

6.  Combining T-cell-specific activation and in vivo gene delivery through CD3-targeted lentiviral vectors.

Authors:  Annika M Frank; Angela H Braun; Lea Scheib; Shiwani Agarwal; Irene C Schneider; Floriane Fusil; Séverine Perian; Ugur Sahin; Frederic B Thalheimer; Els Verhoeyen; Christian J Buchholz
Journal:  Blood Adv       Date:  2020-11-24

7.  Genetic in vivo engineering of human T lymphocytes in mouse models.

Authors:  Tatjana Weidner; Shiwani Agarwal; Séverine Perian; Floriane Fusil; Gundula Braun; Jessica Hartmann; Els Verhoeyen; Christian J Buchholz
Journal:  Nat Protoc       Date:  2021-04-12       Impact factor: 13.491

Review 8.  Surface-Engineered Lentiviral Vectors for Selective Gene Transfer into Subtypes of Lymphocytes.

Authors:  Annika M Frank; Christian J Buchholz
Journal:  Mol Ther Methods Clin Dev       Date:  2018-10-17       Impact factor: 6.698

9.  Transfer and Expression of Small Interfering RNAs in Mammalian Cells Using Lentiviral Vectors.

Authors:  T D Lebedev; P V Spirin; V S Prassolov
Journal:  Acta Naturae       Date:  2013-04       Impact factor: 1.845

10.  V-CARMA: A tool for the detection and modification of antigen-specific T cells.

Authors:  Xi-Zhi J Guo; Stephen J Elledge
Journal:  Proc Natl Acad Sci U S A       Date:  2022-01-25       Impact factor: 12.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.